Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / ABCL - AbCellera inks development agreement with Angios

ABCL - AbCellera inks development agreement with Angios

AbCellera Biologics Inc.
AbCellera (ABCL) and Angios GmbH have entered into a multi-year, multi-target collaboration for the discovery of monoclonal and bispecific antibodies for vascular diseases of the eye.Under the deal, AbCellera will use its full stack, AI-powered antibody discovery platform to generate panels of antibodies for up to three Angios-selected targets to address diabetic retinopathy.Angios will have the rights to develop and commercialize therapeutic products resulting from the collaboration.AbCellera will receive equity and research fees and is eligible for milestone payments and royalties based on the development and commercialization of antibodies generated.AbCellera shares up marginally during premarket trading.

For further details see:

AbCellera inks development agreement with Angios
Stock Information
Company Name: AbCellera Biologics Inc.
Stock Symbol: ABCL
Market: NASDAQ
Website: abcellera.com
Menu
ABCL ABCL Quote ABCL Short ABCL News ABCL Articles ABCL Message Board
Get ABCL Alerts

News, Short Squeeze, Breakout and More Instantly...